Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Trial Details

NCT ID
NCT05147467
Phase
PHASE2
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • APG2575
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Haikou, Hainan, China|20.03421,110.34651
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Subjects who meet each of the following inclusion criteria are eligible to participate in this study:
  • Age ≥18 years old.
  • Pathologically confirmed CLL/SLL according to the 2018 revised IWCLL NCI-WG guidelines, subject with measurable lesions or splenomegaly due to CLL.
  • Expected survival is at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →